Literature DB >> 11467771

Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells.

C L Pethiyagoda1, D R Welch, T P Fleming.   

Abstract

Dipeptidyl peptidase IV (DPPIV) is a 110-kD, trans-membrane, ectoenzyme, with ubiquitous expression. DPPIV has numerous functions including involvement in T-cell activation, cell adhesion, digestion of proline containing peptides in the kidney and intestines, HIV infection and apoptosis, and regulation of tumorigenicity in certain melanoma cells. Constitutively expressed on numerous epithelial cell types, DPPIV is often disregulated in a variety of human malignancies. The most striking evidence of DPPIV down-regulation is found in transformed melanocytes. where nearly 100% of melanomas lack DPPIV expression. We have identified DPPIV as a gene that can alter the invasive potential of a number of melanoma cell lines. By transfecting the full-length cDNA of DPPIV, we have established stable melanoma cell lines that express comparable levels of the DPPIV protein as normal epidermal melanocytes. Matrigel invasion assays were utilized to study the effects of DPPIV expression on the invasive potential of these cells. The parental and vector transfectants readily migrated across the Matrigel while the invasiveness of DPPIV transfected cells was reduced by greater than 75%. The effects on cellular invasion are not attributed to overall growth characteristics, as both DPPIV expressing and non-expressing cells behave comparably in culture. We have also constructed mutants of DPPIV that lack either the extra-cellular serine protease activity or the six amino acid cytoplasmic domain. Both mutants were stably expressed in melanoma cells. Matrigel invasion assays performed with cells expressing the two mutant forms of the protein revealed phenotypic effects similar to wild type function. In this study. we have demonstrated that expression of a proteolytically active form of the DPPIV protein inhibits the invasiveness of malignant melanoma cell lines lacking endogenous DPPIV expression. Furthermore, we have shown that neither the protease activity nor the cytoplasmic domain of DPPIV is required for its anti-invasive activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11467771     DOI: 10.1023/a:1010930918055

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  38 in total

1.  Development of a highly efficient expression cDNA cloning system: application to oncogene isolation.

Authors:  T Miki; T P Fleming; M Crescenzi; C J Molloy; S B Blam; S H Reynolds; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

2.  New chromogenic substrates for X-prolyl dipeptidyl-aminopeptidase.

Authors:  T Nagatsu; M Hino; H Fuyamada; T Hayakawa; S Sakakibara
Journal:  Anal Biochem       Date:  1976-08       Impact factor: 3.365

3.  An efficient directional cloning system to construct cDNA libraries containing full-length inserts at high frequency.

Authors:  T Miki; T Matsui; M A Heidaran; S A Aaronson
Journal:  Gene       Date:  1989-11-15       Impact factor: 3.688

4.  A new in vitro assay for quantitating tumor cell invasion.

Authors:  L A Repesh
Journal:  Invasion Metastasis       Date:  1989

5.  Use of the Membrane Invasion Culture System (MICS) as a screen for anti-invasive agents.

Authors:  D R Welch; T J Lobl; E A Seftor; P J Wack; P A Aeed; K H Yohem; R E Seftor; M J Hendrix
Journal:  Int J Cancer       Date:  1989-03-15       Impact factor: 7.396

6.  Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody.

Authors:  D A Fox; R E Hussey; K A Fitzgerald; O Acuto; C Poole; L Palley; J F Daley; S F Schlossman; E L Reinherz
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

7.  Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease.

Authors:  M L Piñeiro-Sánchez; L A Goldstein; J Dodt; L Howard; Y Yeh; H Tran; W S Argraves; W T Chen
Journal:  J Biol Chem       Date:  1997-03-21       Impact factor: 5.157

8.  Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.

Authors:  W J Rettig; P Garin-Chesa; J H Healey; S L Su; H L Ozer; M Schwab; A P Albino; L J Old
Journal:  Cancer Res       Date:  1993-07-15       Impact factor: 12.701

9.  Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites.

Authors:  L Li; J E Price; D Fan; R D Zhang; C D Bucana; I J Fidler
Journal:  J Natl Cancer Inst       Date:  1989-09-20       Impact factor: 13.506

10.  A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells.

Authors:  U V Wesley; A P Albino; S Tiwari; A N Houghton
Journal:  J Exp Med       Date:  1999-08-02       Impact factor: 14.307

View more
  14 in total

1.  Uric acid inhibition of dipeptidyl peptidase IV in vitro is dependent on the intracellular formation of triuret.

Authors:  Rajesh Mohandas; Laura Sautina; Elaine Beem; Anna Schuler; Wai-Yan Chan; John Domsic; Robert McKenna; Richard J Johnson; Mark S Segal
Journal:  Exp Cell Res       Date:  2014-06-09       Impact factor: 3.905

Review 2.  Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.

Authors:  Eleonore Fröhlich
Journal:  Cell Mol Life Sci       Date:  2010-08-05       Impact factor: 9.261

3.  Transcriptomic and Functional Evidence for Differential Effects of MCF-7 Breast Cancer Cell-Secretome on Vascular and Lymphatic Endothelial Cell Growth.

Authors:  Giovanna Azzarito; Michele Visentin; Brigitte Leeners; Raghvendra K Dubey
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

4.  Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer.

Authors:  Esteban Ballestar; Maria F Paz; Laura Valle; Susan Wei; Mario F Fraga; Jesus Espada; Juan Cruz Cigudosa; Tim Hui-Ming Huang; Manel Esteller
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

Review 5.  DPPIV/CD26: a tumor suppressor or a marker of malignancy?

Authors:  Aline Beckenkamp; Samuel Davies; Júlia Biz Willig; Andréia Buffon
Journal:  Tumour Biol       Date:  2016-03-04

6.  Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior.

Authors:  Ernest Y Tan; Michelle Mujoomdar; Jonathan Blay
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

7.  The Long Noncoding RNA SPRIGHTLY Regulates Cell Proliferation in Primary Human Melanocytes.

Authors:  Wei Zhao; Joseph Mazar; Bongyong Lee; Junko Sawada; Jian-Liang Li; John Shelley; Subramaniam Govindarajan; Dwight Towler; John S Mattick; Masanobu Komatsu; Marcel E Dinger; Ranjan J Perera
Journal:  J Invest Dermatol       Date:  2016-01-29       Impact factor: 8.551

8.  DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis.

Authors:  Xiaoqing Yang; Xinhua Zhang; Rongrong Wu; Qicheng Huang; Yao Jiang; Jianbing Qin; Feng Yao; Guohua Jin; Yuquan Zhang
Journal:  Oncotarget       Date:  2017-01-31

9.  Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation.

Authors:  W T Arscott; A E LaBauve; V May; U V Wesley
Journal:  Oncogene       Date:  2008-11-03       Impact factor: 9.867

10.  Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo.

Authors:  Ivana Z Matić; Marija Ðorđić; Nađa Grozdanić; Ana Damjanović; Branka Kolundžija; Aleksandra Erić-Nikolić; Radan Džodić; Miomir Šašić; Srđan Nikolić; Danijela Dobrosavljević; Sanvila Rašković; Slađana Andrejević; Dušica Gavrilović; Oscar J Cordero; Zorica D Juranić
Journal:  BMC Immunol       Date:  2012-08-21       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.